

MONOCLONAL ANTIBODIES FOR COVID-19: A LIFESAVING TREATMENT YOUR COMMUNITY SHOULD KNOW ABOUT

**A CDC Foundation Webinar Series
For Community-Based Organizations**

**Tuesday, June 29, 2021
3:00-4:00 PM ET**

PRESENTERS



Judy Monroe, MD
CDC Foundation



Lisa Waddell, MD, MPH
CDC Foundation



S. Lawrence Kocot, JD, LLM, MPA
KPMG, LLP



John T. Redd, MD, MPH, FACP
U. S. Department of Health and Human Services



Christian Ramers, MD, MPH
Family Health Centers of
San Diego



Jane Thornhill, MSA
Henry Ford Health System



Felix M. Valbuena, Jr., MD
Community Health and
Social Services Center
(CHASS)



Jayne M. Morgan, MD
Piedmont Healthcare

AGENDA

Welcome

Lisa Waddell, MD, MPH
CDC Foundation

Introductory Remarks

Judy Monroe, MD
CDC Foundation

S. Lawrence Kocot, JD, LLM, MPA
KPMG, LLP

Monoclonal Antibodies for COVID-19: A Lifesaving Treatment Your Community Should Know About

John T. Redd, MD, MPH, FACP
U. S. Department of Health and Human Services

Video: Patients Share Their Experience

Panel One – The Power of Partnerships: How Health Systems Partner with CBOs to Facilitate Access to Monoclonal Antibody Treatment

Christian Ramers, MD, MPH
Family Health Centers of San Diego

Jane Thornhill, MSA
Henry Ford Health System

Panel Two – CBOs and Monoclonal Antibodies: How CBOs Can Improve Awareness of and Access to Monoclonal Antibodies

Felix Valbuena, Jr., MD
Community Health and Social Services Center

Jayne M. Morgan, MD
Piedmont Healthcare

Discussion / Q&A

Call to Action and Adjourn

Lisa Waddell, MD, MPH

Introductory Remarks



Judy Monroe, MD
President and CEO
CDC Foundation

S. Lawrence Kocot, JD, LLM, MPA
Principal and National Leader
Center for Healthcare Regulatory Insight
KPMG, LLP



Monoclonal Antibodies for COVID-19: A Lifesaving Treatment Your Community Should Know About



John T. Redd, MD, MPH, FACP
Chief Medical Officer for the Assistant Secretary for
Preparedness and Response
U. S. Department of Health and Human Services (HHS)



ASPR

Monoclonal Antibodies for COVID-19: A Lifesaving Treatment Your Community Should Know About

**John Redd, MD MPH FACP
Chief Medical Officer**

Office of the Assistant Secretary for Preparedness and Response
U.S. Department of Health and Human Services


June 29th, 2021

UNCLASSIFIED / FOR PUBLIC USE

About monoclonal antibodies

- COVID-19 Monoclonal antibodies (mAbs) are intended for patients with **mild to moderate COVID-19 who are at high risk of developing severe disease resulting in hospitalization**
- mAbs are likely to be most effective when **given early in disease course**
- Outpatient administration of mAbs have the potential to **reduce the relative risk of hospitalizations by up to 70% in high-risk patients**

Summary of COVID-19 Antiviral Therapeutics



1. Per Lilly's request, FDA revoked the EUA for emergency use of bamlanivimab administered alone for the treatment of mild to moderate COVID-19 (on 4/16/2021)

USG activities to support administration of mAbs

Ensure safe, broad, and equitable availability and administration

- 1 **Build product understanding and awareness** – Ensure providers are up to date on CMS reimbursement qualifications, the latest **EUA therapies** (and eligible patient populations), and patients are aware of treatment options
- 2 **Provide information on product location** – Ensure providers have the information to **direct patients to a place to receive treatment**
- 3 **Facilitate product administration** – Ensure providers can **safely administer product** (drug on hand, material, directions, etc.) for current products
- 4 **Track utilization** – **Understand utilization of product** across localities and populations; providers can raise issues/share tips

Asks for community leaders



Promote the awareness of therapies in your local communities

- Share information in local community outlets
- Post information online for individuals to understand that mAbs are available treatment options (neighborhood apps, social media, etc)
- Host outreach events



Understand where treatment locations are in your local community and encourage individuals to seek out mAb treatment



Share experiences to support others in pursuing treatment

- Post information online (blogs, social media, etc)
- Share your experience with HHS/ASPR at COVID19Therapeutics@hhs.gov

Catalog of resources to support distribution and administration of therapies



Informational resources

- [Product Locator Tool](#)
- [HHS Public Health Emergency](#)



Guidance documents

- [Federal COVID-19 Response monoclonal antibody playbook](#)
- Manufacturer specific playbooks
 - [Regeneron](#)
 - [Lilly](#)




Peer experiences

- Weekly calls and open office hours with team for questions

Please email COVID19Therapeutics@hhs.gov if you have any questions

Video: Patients Share Their Experiences



A man with a beard and closed eyes, wearing a black shirt, against a background of horizontal stripes. The man is looking down with his eyes closed, and his mouth is slightly open. The background consists of horizontal stripes in shades of blue, grey, and white.

What really got me was the loss of smell and taste,

Panel One

The Power of Partnerships: How Health Systems Partner with CBOs to Facilitate Access to Monoclonal Antibody Treatment



Christian Ramers, MD, MPH

Assistant Medical Director for Research
and Special Populations
Family Health Centers of San Diego




Jane Thornhill, MSA

Vice President, Henry Ford
Physician Network & ACO
Henry Ford Health System



**FAMILY HEALTH CENTERS
OF SAN DIEGO**



Partnerships to facilitate access to Monoclonal Antibody Treatment

CDC Foundation Webinar

Christian B. Ramers, MD, MPH, AAHIVS

christianr@fhcsd.org - [@cramersmd](https://twitter.com/cramersmd)

Chief, Population Health

Medical Director, Laura Rodriguez Research Institute

Director, Graduate Medical Education

Family Health Centers of San Diego

Clinical Associate Professor – **UC San Diego School of Medicine**

Adjunct Associate Professor – **San Diego State Graduate School of Global Public Health**

Senior Clinical Advisor – **Clinton Health Access Initiative - Global Hepatitis Program**

6/29/21

FHCSD COVID-19 mAb Experience



FAMILY HEALTH CENTERS
OF SAN DIEGO

Coronavirus (COVID-19)

DONATE NOW

CORONAVIRUS (COVID-19)

TELEHEALTH APPOINTMENT

COVID-19 VACCINES

VACCINATION SITES

VACCINE ELIGIBILITY

SITE VOLUNTEERS

COVID-19 TESTING

COVID-19 TREATMENT

FACE COVERINGS

SELF-CARE

SAFETY MEASURES

CA NOTIFY: COVID-19 EXPOSURE
NOTIFICATIONS

Q What are the risks?

A Some patients may experience mild side effects, including itching, shortness of breath or low blood pressure. However, these side effects are very rare. People may also experience pain, soreness or bruising around the IV site. As with any medication, there is a very small chance of having an allergic reaction.

Q Is there an antibiotic I can take instead?

A No. COVID-19 is caused by a virus, and antibiotics only work against bacteria. Currently, there are no other treatments effective against COVID-19 that can be given outside a hospital.

Q How effective is it?

A Monoclonal antibody infusions prevent the disease from becoming more severe or requiring a hospital visit. Studies have shown that the infusions reduce the chances of severe COVID-19 by 80%. Most patients report improvement of symptoms within 24 to 48 hours after treatment.

Q Who is eligible for the treatment?

A People who have tested positive and are at a greater risk of developing severe COVID-19 symptoms get the most benefit from the treatment. This includes those over 65 and with chronic medical conditions, such as diabetes or asthma, and those who are overweight or obese. Your provider can determine if monoclonal antibody therapy is right for you.

The treatment can only be given within ten days of illness, so it is important to seek medical care and take a test for COVID-19 as soon as you develop symptoms.

Q Do I still need the vaccine if I received this treatment?

A If you received monoclonal antibody therapy, you do not need a vaccine until 90 days after treatment. The vaccines likely will not be effective until the antibodies have had a chance to go away. However, you should still get vaccinated once the 90-day period is over for stronger, longer-lasting protection from COVID-19.

GET TESTED.
GET TREATED.
CRUSH COVID.



IS THERE A TREATMENT FOR COVID-19?

Yes! If you've tested positive for COVID-19 and your symptoms began in the past 10 days, you may be eligible for a free treatment near you.

FIND A TREATMENT CENTER →


As of 6/25/21...

319 patients have received mAb infusions (Bamlanivimab, Bamlanivimab/Etesevimab, or Casirivimab/Imdevimab) at FHCSD




4 total hospitalizations (rate of 1.25%)

Expected hospitalization rate in those at risk for severe disease possibly 7 or 8%? (22-26)

Timing and awareness are **CRITICAL** to ensure efficacy of COVID mAbs




EXPOSURE



COVID-19 Treatment | Monoclonal Antibody Therapy (mAbs) | San Diego County

Cumulative (as of 6/19/21) COVID-19 Case Rates by zip code, San Diego



- Obvious and persistent geographic disparity of COVID-19 cases along racial and sociodemographic characteristics

The Inverse Equity Hypothesis

- **1979 – Inverse Care Law:** Availability of good medical care tends to vary inversely with the need for it in the population served
- **2000 – Inverse Equity Hypothesis:** Newly introduced health interventions will be initially adopted by the wealthier segments of a population who likely had the least need or such interventions
 - In the short term, absolute health inequalities would increase and only decline as the intervention gradually reaches the most deprived sectors of the population, by which time coverage among the most privileged sectors was already close to 100%


“Any Serious Examination of epidemic disease has always shown that microbes make a ***preferential option for the poor***. But medicine and its practitioners, even in public health, do so all too rarely.”

- Paul Farmer, MD – *Partners in Health*

1. Hart JT. The inverse care law. Lancet 1971;1(7696): 405-412


2. Victora CG, et al Explaining Trends in inequities: evidence from Brazilian child health studies. Lancet 2000; 356(9235): 1093-1098

Mapping of Social Determinants of Health vs. mAb Availability



2016 CDC Social Vulnerability Index

<https://svi.cdc.gov/map.html>



COVID-19 mAb infusion sites

<https://covid.infusioncenter.org/> - San Diego Infusion centers offering COVID-19 mAbs

Early Lessons Learned in COVID-19 mAb Implementation

- **Community Awareness** is key to improving availability and uptake of COVID-19 monoclonal antibody treatments
- **Integration of Testing, Telemedicine, and linkage to COVID-19 mAb Treatment** requires community involvement and high levels of collaboration rarely seen in the US healthcare system
- **A Call to Action for Community-Based Organizations:**
 - Help get the word out about the ‘unsung hero’ of the COVID-19 Pandemic
 - Anyone involved in COVID-19 community outreach or testing must be aware of local mAb infusion resources
 - Increased availability of COVID-19 mAbs in a community **will save lives**



mAB Infusion Update

Henry Ford Health System

June 2021




ALL FOR YOU

Henry Ford mAB Infusion Volume Trend / Demographics

mAB Infusion Volume by Week




HHS Expanded Outreach/Capacity



mAB Infusion by Race/Ethnicity


Gender

mAB Infusion by Age Group



MAB Infusion Workflow – Current State

Future State



Panel Two

CBOs and Monoclonal Antibodies: How CBOs Can Improve Awareness of and Access to this Lifesaving Treatment



Felix Valbuena, Jr., MD
Chief Executive Officer
Community Health and Social
Services Center (CHASS)



Jayne M. Morgan, MD
Clinical Director, COVID-19
Task Force Lead
Piedmont Healthcare



la Salud de la gente es un derecho humano.



We believe health care is a basic human right.



CHASS Center

The Community Health and Social Services Center was formed to develop, promote and provide comprehensive, accessible and affordable quality primary health care and support services to all residents of the community, with special emphasis on the underserved African American and Latino populations. CHASS is committed to the overall well-being of the community.

- Established in 1970.
- The belief that health care is a basic human right.
- The understanding that effective health care requires a comprehensive and holistic approach.
- The knowledge that meaningful access requires a community-based approach and a culturally competent staff.





CBOs and Monoclonal Antibodies: How CBOs Can Improve Awareness of and Access to this Lifesaving Treatment



Jayne M. Morgan, MD
Clinical Director, COVID-19 Task Force Lead
Piedmont Healthcare

**MONOCLONAL ANTIBODIES
FOR COVID-19:
A LIFESAVING TREATMENT
YOUR COMMUNITY SHOULD
KNOW ABOUT**

Discussion

+

Q&A



PRESENTERS



John T. Redd, MD, MPH, FACP
U. S. Department of Health and Human Services



Christian Ramers, MD, MPH
Family Health Centers of
San Diego



Jane Thornhill, MSA
Henry Ford Health System



Felix M. Valbuena, Jr., MD
Community Health and Social
Services Center (CHASS)



Jayne M. Morgan, MD
Piedmont Healthcare

Call to Action

MONOCLONAL ANTIBODIES for COVID-19:

A Lifesaving Treatment Your Community
Should Know About

ACTIONS

- Get vaccinated
- Obtain more information on monoclonal antibody treatment and share with your constituents
- Download the fact sheet and share this valuable information with your communities
- Wear a mask
- Watch your distance

PLUS

- CDC Foundation remains committed to supporting CBOs and working with you

LEARN MORE

- Visit HHS information on Monoclonal Antibodies [Combat COVID - Monoclonal Antibodies for High-Risk COVID-19 Positive Patients](#)
- Visit [Crushcovid.com](https://www.cdc.gov/crushcovid)

Resources for Community-Based Organizations



[cdcfoundation.org/COVID-19-community-resources](https://www.cdcfoundation.org/COVID-19-community-resources)

Thank You!

MONOCLONAL ANTIBODIES for COVID-19:

A Lifesaving Treatment Your Community
Should Know About

- Thank you again for attending.
 - As you log out, please take a moment and complete the **brief questionnaire**.
 - Your ideas will help us as we plan future webinars and assist in providing capacity building assistance to CBOs.
- Today's slides and a recording of this webinar will be posted online; a link will be provided.